Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT05774951 · ClinicalTrials.gov registry record · Phase 3

A Study of Camizestrant in ER+/HER2- Early Breast Cancer After at Least 2 Years of Standard Adjuvant Endocrine Therapy

A Phase 3 study of Breast Cancer, Early Breast Cancer, sponsored by AstraZeneca.

Recruiting
Registry status
Phase 3
Development phase
4,300
Enrollment target
20
Study locations

NCT05774951 is a Phase 3 study of Breast Cancer, Early Breast Cancer that is actively recruiting participants, run by AstraZeneca. The registered enrollment target is 4,300 participants. The trial reports 20 study locations across 8 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT05774951, a Phase 3 study of Breast Cancer, Early Breast Cancer, is actively recruiting participants, sponsored by AstraZeneca.

RECRUITING
Registry status
Phase 3
Development phase
4,300 participants
Enrollment target
20
Study locations

Study Summary

This is a Phase III open-label study to assess if camizestrant improves outcomes compared to standard endocrine therapy in patients with ER+/HER2 - early breast cancer with intermediate or high risk for disease recurrence who completed definitive locoregional therapy (with or without chemotherapy) and standard adjuvant endocrine therapy (ET) for at least 2 years and up to 5 years. The planned duration of treatment in either arm of the study is 60 months.

Conditions Studied

Breast Cancer, Early Breast Cancer

Interventions

  • DRUG Camizestrant
  • DRUG Tamoxifen
  • DRUG Anastrozole
  • DRUG Letrozole
  • DRUG Exemestane

Study Locations (20)

California

  • Research Site - Anaheim
  • Research Site - Beverly Hills
  • Research Site - Concord
  • Research Site - Corona
  • Research Site - Fountain Valley
  • Research Site - Greenbrae
  • Research Site - Los Alamitos
  • Research Site - Palo Alto
  • Research Site - San Diego
  • Research Site - San Diego
  • Research Site - Whittier

Alabama

  • Research Site - Birmingham
  • Research Site - Dothan

Florida

  • Research Site - Fort Myers
  • Research Site - Gainesville

Alaska

  • Research Site - Anchorage

Arizona

  • Research Site - Chandler

Arkansas

  • Research Site - Hot Springs

Colorado

  • Research Site - Aurora

Connecticut

  • Research Site - Hartford

Trial Details

FieldValue
Enrollment Target 4,300 participants
Start Date 2023-03-31
Est. Completion 2036-05-29
Phase Phase 3

Sponsor

AstraZeneca

1,285 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT05774951

The ClinicalTrials.gov registry entry for NCT05774951 describes a study currently listed as recruiting, categorized as Phase 3. The registered enrollment target is 4,300 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is AstraZeneca, which has 1,285 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Breast Cancer, Early Breast Cancer appearing as the primary indexed condition, and to 5 interventions - of which Camizestrant is the first listed.

NCT05774951 reports 20 study locations spanning 8 distinct geographic areas - top geographies include California, Alabama, Florida.

Frequently Asked Questions

What is clinical trial NCT05774951 about?

NCT05774951 is a clinical study titled "A Study of Camizestrant in ER+/HER2- Early Breast Cancer After at Least 2 Years of Standard Adjuvant Endocrine Therapy". This is a Phase III open-label study to assess if camizestrant improves outcomes compared to standard endocrine therapy in patients with ER+/HER2 - early breast cancer with intermediate or high risk for disease recurrence who completed definitive locoregional therapy (with or without chemotherapy) a...

What is the current status of trial NCT05774951?

This trial is currently recruiting. It is a Phase 3 study. The enrollment target is 4,300 participants. The study started on 2023-03-31. Estimated completion is 2036-05-29.

What conditions does trial NCT05774951 study?

This clinical trial studies the following conditions: Breast Cancer, Early Breast Cancer.

What interventions are being tested in trial NCT05774951?

The interventions under investigation include: Camizestrant (DRUG), Tamoxifen (DRUG), Anastrozole (DRUG), Letrozole (DRUG), Exemestane (DRUG).

Who is sponsoring clinical trial NCT05774951?

This trial is sponsored by AstraZeneca, which has 1,285 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT05774951 being conducted?

This trial has 20 study locations across Alabama, Alaska, Arizona, Arkansas, California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Breast Cancer, Early Breast Cancer

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Breast Cancer, Early Breast Cancer

All registered trials for this condition

Alabama

All trials with a study site in Alabama

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.